UCSF adult and pediatric clinical trials

UCSF Brain Tumor Center Clinical Trials

Our clinical trials evaluate a broad range of innovative therapies for both adults and children with brain tumors. 

Advanced Search for Physicians
Identify Relevant Clinical Trials
Clinical Trial Phase
Intervention Model
Treatment Modality
Which of the following treatments has the patient already received?*
Genetic Features*
  • Recruiting Recruiting
  • Pediatrics Pediatrics
  • On Hold On Hold
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas (PNOC017)
Conditions
Glioma
Astrocytoma
Glioblastoma (grade IV)
Anaplastic astrocytoma (grade III)
Diffuse astrocytoma (grade II)
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Ependymoma
Oligodendroglioma
This phase I clinical trial will evaluate the safety, efficacy and clinical activity of BGB-290 in combination with temozolomide, for treating adolescents and young adults with IDH1/2-mutant glioma (grades I-IV).
Recruiting
Impact of Cannabis and Synthetic Cannabinoid Use on Quality of Life of Patients with Central Nervous System Tumors
Conditions
Glioma
Astrocytoma
Glioblastoma (grade IV)
Anaplastic astrocytoma (grade III)
Diffuse astrocytoma (grade II)
Chordoma
Schwannoma (grade 1)
Craniopharyngioma
Oligodendroglioma
Meningioma
Pituitary Tumor
This observational study will collect data to better understand our patient population and their behavior around cannabis, as well as clinical outcomes that might be linked to the consumption of cannabis.
Recruiting
Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
Conditions
Glioma
Astrocytoma
Pilocytic astrocytoma (grade I)
Diffuse astrocytoma (grade II)
Pleomorphic xanthoastrocytoma (grades II-III)
Summary

This phase II clinical trial will evaluate the efficacy and side effects of larotrectinib in treating patients with previously untreated TRK fusion solid tumors (including central nervous system (CNS) tumors) and relapsed TRK fusion acute leukemia. 

Recruiting
Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
Conditions
Glioma
Astrocytoma
Pilocytic astrocytoma (grade I)
Diffuse astrocytoma (grade II)
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
Atypical Teratoid / Rhabdoid Tumor (AT/RT)
Medulloblastoma
Ependymoma
This phase I clinical trial will study a novel drug called ALRN-6924 for treating children and young adults with recurrent or refractory solid tumors, brain tumors, lymphoma or leukemia. 
Recruiting
Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive Enhancing IDH-1 Mutant Astrocytomas
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Pleomorphic xanthoastrocytoma (grades II-III)
Diffuse astrocytoma (grade II)
This phase I study will evaluate the safety, dose-limiting toxicities, and preliminary efficacy of vorasidenib in combination with pembrolizumab in participants with recurrent or progressive enhancing isocitrate dehydrogenase-1 (IDH-1) mutant astrocytomas.
Recruiting
Trametinib and Everolimus for the Treatment of Pediatric and Young Adult Patients With Recurrent Low Grade Gliomas (PNOC021)
Conditions
Glioma
Astrocytoma
Diffuse astrocytoma (grade II)
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Subependymal giant cell astrocytoma (grade I)
Ependymoma
Oligodendroglioma
This phase I trial study will evaluate the dosage, safety and efficacy of trametinib and everolimus in treating pediatric and young adult patients with recurrent low-grade glioma.
Recruiting

Stay Informed